Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †

SIMPLE SUMMARY: Trials suggest no differences in immunotherapy treatment between older and younger patients, but mainly young patients with a good performance status were included in these trials. The aim of this study was to describe the treatment patterns and outcomes of “real-world” older patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: de Glas, Nienke A., Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P., van der Veldt, Astrid A. M., Suijkerbuijk, Karlijn P. M., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., de Groot, Jan-Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S., ten Tije, Albert J., Vreugdenhil, Gerard, Wouters, Michel W. J. M., Portielje, Johanneke E. A., Kapiteijn, Ellen W.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8201158/
https://ncbi.nlm.nih.gov/pubmed/34198950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112826
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados